Redefining Criteria to Ensure Adequate Sentinel Lymph Node Biopsy With Dual Tracer for Breast Cancer

BACKGROUND: For sentinel lymph node biopsy (SLNB) in patients with breast cancer, the dual tracer of blue dye and radioisotope with the 10% rule that all nodes with radioactive count of 10% or more of the hottest node ex vivo should be removed is widely accepted. However, the cut-off point of radioa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Li, Yang, Jiqiao, Du, Zhenggui, Liang, Faqing, Xie, Yanyan, Long, Quanyi, Chen, Jie, Zeng, Helin, Lv, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744718/
https://www.ncbi.nlm.nih.gov/pubmed/33344240
http://dx.doi.org/10.3389/fonc.2020.588067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744718/
https://www.ncbi.nlm.nih.gov/pubmed/33344240
http://dx.doi.org/10.3389/fonc.2020.588067

Ejemplares similares